title: Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
abstract: BACKGROUND
  Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an open-label, multicentre phase II study in patients with previously treated, advanced NSCLC. Patients > or =18 years with stage IIIB/IV NSCLC after failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety.
  
  
  RESULTS
  Of 47 patients receiving sunitinib, one patient achieved a confirmed partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) > or =8 weeks. Five patients had SD>6 months. Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5). Treatment was generally well tolerated.
  
  
  CONCLUSIONS
  The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.
authors.affiliation: Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy. silvia.novello@unito.it
authors.forename: S
authors.initials: S
authors.lastname: Novello
authors.forename: G V
authors.initials: GV
authors.lastname: Scagliotti
authors.forename: R
authors.initials: R
authors.lastname: Rosell
authors.forename: M A
authors.initials: MA
authors.lastname: Socinski
authors.forename: J
authors.initials: J
authors.lastname: Brahmer
authors.forename: J
authors.initials: J
authors.lastname: Atkins
authors.forename: C
authors.initials: C
authors.lastname: Pallares
authors.forename: R
authors.initials: R
authors.lastname: Burgess
authors.forename: L
authors.initials: L
authors.lastname: Tye
authors.forename: P
authors.initials: P
authors.lastname: Selaru
authors.forename: E
authors.initials: E
authors.lastname: Wang
authors.forename: R
authors.initials: R
authors.lastname: Chao
authors.forename: R
authors.initials: R
authors.lastname: Govindan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib